COVID-19: Planning global Phase 2 outpatient trial for bemnifosbuvir (AT-527) designed to support anticipated combination trials
HCV: Obtained from Merck an exclusive worldwide license to ruzasvir (RZR), a Phase 2-ready, oral, potent NS5A inhibitor for development in combination with bemnifosbuvir as a pan-genotypic regimen for hepatitis C (HCV)
Dengue: Initiating AT-752 Phase 2 proof-of-concept program for dengue fever
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.